02-12-07

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Alexandria, VA 22313-1450 on the date shown below.

Signature

Typed or printed name

Total Number of Pages in This Submission

Application Number 10/656,895 Filing Date September 5, 2003 Scott A. Waldman First Named Inventor Art Unit 1643 Examiner Name Rawlings, Stephen L. TJU0007-103 (WAL-SCO.004) Attorney Docket Number

	ENCLOSURES (check all that a	рріу)	
Fee Transmittal Form	☐ Drawing(s)	□ A	fter Allowance Communication to TC
Fee Attached	Licensing-related Papers	. —	sppeal Communication to Board of Appeals and Interferences
Amendment / Reply	Petition	_	appeal Communication to TC Appeal Notice, Brief, Reply Brief)
After Final	Petition to Convert to a Provisional Application	□ P	Proprietary Information
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	s	Status Letter
Extension of Time Request	Terminal Disclaimer		Other Enclosure(s) please identify below):
Express Abandonment Request	Request for Refund CD, Number of CD(s)		s SB08a/ Form SB08b (2pp.); 5 References I, (4) References Enclosed.
Supplemental Information Disclosure Statement	☐ Landscape Table on CD		
Certified Copy of Priority Document(s)	Remarks EXPRESS MAIL LABEL NO: EV 7709	72214 U	es
Reply to Missing Parts/ Incomplete Application	DATE OF DEPOSIT: February 8, 2007	7	
Reply to Missing Parts under 37 CFR1.52 or 1.53			
SIG	NATURE OF APPLICANT, ATTORN	IEY, OF	RAGENT
Firm	Cozen O'Connor		
Signature	M		
Printed Name	Mark DeLuca		
Date	I Fabrican/X 2007	Reg. No.	33,229
	CERTIFICATE OF TRANSMISSIO	N/MAII	LING
I hereby certify that this corresponder	nce is being facsimile transmitted to the	USPTO	or deposited with the United States Postal

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

OCKET NO: TJU0007-103

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Scott A. Waldman et al.

Serial No.: 10/656,895

Group Art Unit: 1643

Filing Date: September 5, 2003

Examiner: Rawlings, Stephen L.

For:

Compositions That Specifically Bind to Colorectal Cancer Cells and Methods of

Using the Same

Express Mail Label No. EV 770972214 US Date of Deposit: February 8, 2007

PATENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed:

within three months of the filing date of the patent application.
within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
before the mailing date of a first Office Action on the merits.
before the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under § 1.114.

\boxtimes	of a Redate of	the mailing date of a first Office Action on the merits or after the filing equest for Continued Examination under § 1.114, but before the mailing of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of ance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
		the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
		or
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
		No fee is owed by the applicant(s).
	Statem Final S C.F.R.	cordance with 37 C.F.R. § 1.129(a), this Information Disclosure nent is being filed in connection with the first or second After Submission, and accordingly is accompanied by the Statement under 37 § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in F.R. § 1.17(p), is attached.
	Notice with, 1 Statem	the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a e of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously the payment of the Issue Fee, and accordingly is accompanied by the nent under 37 C.F.R. § 1.97(e), and the Fee of \$180.00 set forth in 37 . §1.17(p).
\boxtimes	-	s of Citations listed on the attached PTO Form SB/08b, formerly known D Form 1449, are enclosed.
	EXCE	CPT THAT:
		In view of the voluminous nature of references, and the likelihood that these reference are available to the Examiner, copies are not enclosed herewith.
		In accordance with 37 C.F.R. § 1.98(d), copies of references identified as Citation Nos. 28-33 listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.
		If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
Stater	nent un	der 37 C.F.R. § 1.97(e)
	in the foreign	Information Disclosure Statement was cited in a communication from a patent office in a counterpart foreign patent application not more than months prior to the filing of the Information Disclosure Statement.

State	ment under 37 C.F.R. § 1.704(d)
	The undersigned attorney hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and the communication was not received by any individual designated in §1.56(c) more than 30 days prior to the filing of the Information Disclosure Statement.
Fees	
	No Fee is owed by the applicant(s).
\boxtimes	The Supplemental Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.
	The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.
Meth	od of Payment of Fees
	Attached is a check in the amount of \$ This form is submitted in duplicate.
\boxtimes	Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
\boxtimes	Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
	No fee or Statement is required under 37 C.F.R. § 1.97(b).
	Respectfully submitted,

Mark DeLuca

Registration No. 33,229

Dated: February 8, 2007

COZEN O'CONNOR, P.C. 1900 Market Street, 5th Floor Philadelphia, PA 19103-3508 (215) 665-2000 - Telephone (215) 665-2013 - Facsimile

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known				
				Application Number	10/656,895	_		
INFO	PRMATION	DIS	CLOSURE	Filing Date	September 5, 2003			
STATEMENT BY APPLICANT		First Named Inventor	Scott A. Waldman					
				Art Unit	1643			
	(Use as many she	eets as	necessary)	Examiner Name	Stephen L. Rawlings			
Sheet	1	of	2	Attorney Docket Number	TJU0007-103 (WAL-SCO.895)			

			U.S. PATENT D	OCUMENTS	
Examiner	Cite	Document Number	Publication/Issue Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan
Initials *	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	Silver Describerts	Passages or Relevant Figures Appear
	1.	US - 4,818,709	04-04-1989	Primus et al.	
	 				
	<u> </u>				
					
				-	
	ļ				
	1				
	<u> </u>				

		FOREIGI	N PATENT DOC	UMENTS		
	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Date/Filing Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶
						
			 			
			ļ		<u> </u>	
			 	- · · · · · · · · · · · · · · · · · · ·		
			 			

Examiner Signature	Date Considered	_	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known Application Number 10/656,895 INFORMATION DISCLOSURE September 5, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor Scott A. Waldman Art Unit 1643 (Use as many sheets as necessary) Examiner Name Stephen L. Rawlings TJU0007-103 (WAL-SCO.895) 2 Attorney Docket Number Sheet of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	2.	Francoeur, et al., "Alternative splicing of natriuretic peptide A and B receptor transcripts in the rat brain," Clin Exp Pharmacol Physiol Suppl. (1995), 22(1):S172-4.	
	3.	Maclean et al., "Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant," Cancer Immunol Immunother. (1993), 36(4):215-22.	
	4.	Roth et al., "Ontogeny of glycine transport in isolated rat renal tubules," Am J Physiol. (1977), 233(3):F241-6.	
	5.	Tallerico-Melnyk et al., "A novel guanylyl cyclase-A isoform: rat GC-A1 identification and mRNA localization to renal papilla and adrenal," <i>Biochem Biophys Res Commun.</i> (1995), 209(3):930-5.	
			-

		_
Evaminor	Date	1
Examiner	Date	1
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the disvidual process. case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.